Skip to main content
Toggle navigation
Login
Home
Back
Favorite
0
Like
Facebook
Tweet
March
Session VI: Hepatobiliary Cancers
Debate: Optimal Second-Line Treatment in Hepatocellular Carcinoma? Tyrosine Kinase Inhibitors vs. IO - TYROSINE KINASE INHIBITORS
Saturday, March 26, 2022
12:10 PM – 12:18 PM
Debate Speaker(s)
Milind M. Javle, MD
MD Anderson Cancer Center, The University of Texas